Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients

[1]  H. Okagbue,et al.  Survival Analysis of Cancer Patients in North Eastern Nigeria from 2004 – 2017 – A Kaplan - Meier Method , 2019, Open access Macedonian journal of medical sciences.

[2]  I. Ellis,et al.  Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications. , 2017, Pathology, research and practice.

[3]  R. Sánchez-Prieto,et al.  CHK1 expression in Gastric Cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response , 2016, Scientific Reports.

[4]  Mbbs Md FRCPath Donald N. Pritzker Vinay Kumar.  Robbins and Cotran pathologic basis of disease , 2015 .

[5]  I. Ellis,et al.  Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response , 2015, British Journal of Cancer.

[6]  A. Ribeiro,et al.  P-Cadherin Linking Breast Cancer Stem Cells and Invasion: A Promising Marker to Identify an “Intermediate/Metastable” EMT State , 2014, Front. Oncol..

[7]  M. Dimopoulos,et al.  Ongoing Spontaneous DNA Damage and the Role of Aberrant Epigenome in Multiple Myeloma , 2014 .

[8]  Leslie K. Ferrarelli.  ZEB1 Teams Up with the DNA Damage Response , 2014, Science Signaling.

[9]  A. Massey,et al.  Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers , 2014, BMC Cancer.

[10]  W. Woodward,et al.  ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1 , 2014, Nature Cell Biology.

[11]  C. Benes,et al.  Whole chromosome instability resulting from the synergistic effects of pRB and p53 inactivation , 2014, Oncogene.

[12]  I. Ellis,et al.  Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart. , 2014, The Malaysian journal of pathology.

[13]  Youwei Zhang,et al.  Roles of Chk1 in cell biology and cancer therapy , 2014, International journal of cancer.

[14]  A. Massey,et al.  Chk 1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers , 2014 .

[15]  D. Clawson,et al.  Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor , 2014, Investigational New Drugs.

[16]  Yong Li,et al.  Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance , 2013, Cell Death and Disease.

[17]  I. Ellis,et al.  Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women , 2013, ISRN oncology.

[18]  X. Wang,et al.  Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer , 2013, Oncogene.

[19]  Pablo Huertas Sánchez,et al.  Regulation of DNA double strand break repair pathways , 2013 .

[20]  I. Ellis,et al.  Clinical and Molecular Significance of Poly (ADP-Ribose) Polymerase-1 (PARP-1) in Breast Cancer of African Women and its Potential as a Targeted Therapy , 2013 .

[21]  Xiaoshan Feng,et al.  Chk1 knockdown confers radiosensitization in prostate cancer stem cells. , 2012, Oncology reports.

[22]  E. Anderssen,et al.  Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma , 2012, PloS one.

[23]  I. Ellis,et al.  Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women , 2012, Breast Cancer Research and Treatment.

[24]  M. Inagaki,et al.  Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti‐cancer therapy? , 2012, Cancer science.

[25]  Jian Hong,et al.  CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. , 2012, The Journal of clinical investigation.

[26]  E. Brown,et al.  Chk'ing p53-deficient breast cancers. , 2012, The Journal of clinical investigation.

[27]  M. Ellis,et al.  Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. , 2012, The Journal of clinical investigation.

[28]  O. Sansom,et al.  Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis , 2012, Oncogene.

[29]  O. Fernandez-Capetillo,et al.  An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation , 2012, The Journal of experimental medicine.

[30]  Ju-Hee Lee,et al.  Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors , 2011, Proceedings of the National Academy of Sciences.

[31]  W. Seghezzi,et al.  Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening , 2011, Molecular Cancer Therapeutics.

[32]  I. Ellis,et al.  Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer , 2011, Breast Cancer Research and Treatment.

[33]  Zhuling Yang,et al.  [Expression of checkpoint kinase 1 and polo-like kinase 1 and its clinicopathological significance in benign and malignant lesions of the stomach]. , 2010, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.

[34]  C. Deng,et al.  Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53 , 2010, Oncogene.

[35]  I. Ellis,et al.  The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers , 2010, The Journal of pathology.

[36]  I. Ellis,et al.  Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens , 2010, Histopathology.

[37]  Yun Dai,et al.  New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network , 2010, Clinical Cancer Research.

[38]  L. Larue,et al.  PI3K/AKT Pathway and the Epithelial-Mesenchymal Transition , 2010 .

[39]  Lye Mun Tho,et al.  The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. , 2010, Advances in cancer research.

[40]  C. Kemp,et al.  Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer , 2009, Oncogene.

[41]  L. Larue,et al.  Chapter 2 PI 3 K / AKT Pathway and the Epithelial – Mesenchymal Transition , 2009 .

[42]  T. Helleday,et al.  Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control , 2008, Proceedings of the National Academy of Sciences.

[43]  Å. Borg,et al.  Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer , 2008, Breast Cancer Research.

[44]  Stephen Green,et al.  AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies , 2008, Molecular Cancer Therapeutics.

[45]  P. O'Connor,et al.  Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 , 2008, Molecular Cancer Therapeutics.

[46]  S. W. Lee,et al.  MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene , 2008, Oncogene.

[47]  D. Gerber,et al.  Targeted therapies: a new generation of cancer treatments. , 2008, American family physician.

[48]  J. Nickoloff,et al.  Regulation of DNA double-strand break repair pathway choice , 2008, Cell Research.

[49]  J. Casal,et al.  A Proteomics Analysis of Cell Signaling Alterations in Colorectal Cancer*S , 2007, Molecular & Cellular Proteomics.

[50]  B. Orelli,et al.  RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. , 2007, Cancer research.

[51]  Kathleen Marchal,et al.  The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas. , 2007, Cancer research.

[52]  H. Niida,et al.  Specific Role of Chk1 Phosphorylations in Cell Survival and Checkpoint Activation , 2007, Molecular and Cellular Biology.

[53]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[54]  Zhan Xiao,et al.  Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics , 2006, International journal of cancer.

[55]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[56]  Abdul-Rasheed K. Adesunkanmi,et al.  The severity, outcome and challenges of breast cancer in Nigeria. , 2006, Breast.

[57]  H. Senn,et al.  Multitarget stereotactic core-needle breast biopsy (MSBB)--an effective and safe diagnostic intervention for non-palpable breast lesions: a large prospective single institution study. , 2006, Breast.

[58]  S. Jackson,et al.  Rapid PIKK-Dependent Release of Chk1 from Chromatin Promotes the DNA-Damage Checkpoint Response , 2006, Current Biology.

[59]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  David J. Chen,et al.  Independent and sequential recruitment of NHEJ and HR factors to DNA damage sites in mammalian cells , 2005, The Journal of cell biology.

[61]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[62]  C. Prives,et al.  The Chk2 protein kinase. , 2004, DNA repair.

[63]  J Silvio Gutkind,et al.  Global Gene Expression Profile of Nasopharyngeal Carcinoma by Laser Capture Microdissection and Complementary DNA Microarrays , 2004, Clinical Cancer Research.

[64]  Jiri Bartek,et al.  Targeting the checkpoint kinases: chemosensitization versus chemoprotection , 2004, Nature Reviews Cancer.

[65]  A. Olshen,et al.  BARD1 Participates with BRCA1 in Homology-Directed Repair of Chromosome Breaks , 2003, Molecular and Cellular Biology.

[66]  Lawrence C. Brody,et al.  BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage , 2002, Nature Genetics.

[67]  P. J. Welch,et al.  Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Xiaoshan Feng,et al.  Chk 1 knockdown confers radiosensitization in prostate cancer stem cells , 2022 .